Recent News
Read ArticleThe NEJM has published a randomized controlled trial in giant-cell arteritis (GCA) patients, demonstrating significant efficacy and safety of upadacitinib (UPA), given as 15 mg daily, as compared to placebo.A total of 209 GCA patients (70% had had new onset GCA) were randomized in a 2:
To promote broader avail. of biosimilars in EU, EMA has proposed a new path for new biosimilars, omitting comparative clinical trial data, as long as biosimilar shows structural & functional comparability, w/ pharmacokinetic & interaction data (relative to reference product) https://t.co/24aTCuDwdO
Dr. John Cush @RheumNow ( View Tweet)
Delays in RA diagnosis can lead to irreversible joint damage. 14-3-3eta complements traditional biomarkers to improve early detection and monitoring. Dr. @WalterMaks outlines its clinical value. Sponosred by Augurex. Learn more: https://t.co/MtLFsRnbrK https://t.co/7n3A6fGCOf
Links:
Dr. John Cush @RheumNow ( View Tweet)
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Sponsored by UCB
https://t.co/mSpsLyKO5h https://t.co/t5gaVOKfqu
Dr. John Cush @RheumNow ( View Tweet)
Joint Implant Metals May Be Leaking
Patients with metal-containing joint replacements had significantly higher concentrations of cobalt in their cerebrospinal fluid (CSF) relative to patients without arthroplasties, researchers reported.
https://t.co/ubDhWqtTSL https://t.co/GjMnog8mcJ
Dr. John Cush @RheumNow ( View Tweet)
1st Line Biologics vs. csDMARDs in Adult Still's Disease
A German multicentre, retrospective study assessed the first-line efficacy of biologics and conventional synthetic DMARD therapy in patients with adult-onset Still's disease (AOSD) and found biologic agents were https://t.co/EeSuBiYx5Q
Dr. John Cush @RheumNow ( View Tweet)
Time to first musculoskeletal (MSK) response with an IL-23i in PsA: Phase 3 post hoc analyses
View time to first response in key MSK efficacy outcomes and PROs in PsA patients treated with an IL-23i. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/3p4NIu4jHF https://t.co/dtr833kxyb
Dr. John Cush @RheumNow ( View Tweet)
Review article shows that in psoriasis pts, adding #MTX to TNFi increases efficacy, but there is limited data on adding MTX to either IL-17 or IL-23. But in Psoriatic Arthritis (PsA), adding MTX provides no added efficacy compared to biologic monotherapy https://t.co/FiSFIjpsXo https://t.co/ComFg253u9
Dr. John Cush @RheumNow ( View Tweet)
Diagnostic delays and Undertreatment of Psoriatic Arthritis
EurekAlert!
New research from the University of Bath in the UK reveals delayed diagnosis and undertreatment of psoriatic arthritis often results in irreversible damage to joints.
Read Article
NIH Complimentary Medicine overview of Music Therapy - preliminary research suggests that music interventions may be helpful for anxiety, depression, pain control, dementia, multiple sclerosis, Parkinson’s disease, etc https://t.co/UGsfT7lITQ https://t.co/DrJm4JdEuY
Dr. John Cush @RheumNow ( View Tweet)
EMA approved a record 28 biosimilars in 2024 for cancer, osteoporosis, macular degeneration, and immune-related diseases like plaque psoriasis, ulcerative colitis, and Crohn’s disease https://t.co/NNzKRalLvF https://t.co/nfX082a7ON
Dr. John Cush @RheumNow ( View Tweet)
Systematic review 21 studies showed potential of RTX with IVIg in autoimmune Dz - 10 studies on pemphigus (85 pts) - all Positive outcomes except 1 paraneoplastic pemphigus. Infections (eg, P. jirovecii pneumonia) seen in 3. 11 studies (24 pts) Rx'd neuropathies, CND lupus& https://t.co/l1BZ7sObg2
Dr. John Cush @RheumNow ( View Tweet)
Consensus on Bone Turnover Biomarkers in Osteoporosis
A new consensus paper, published by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), the International Osteoporosis Foundation (IOF), and the https://t.co/lq1odNBLdZ
Dr. John Cush @RheumNow ( View Tweet)
Consensus Against Interventional Injections for Chronic Spinal Pain
BMJ has published a clinical practice guideline resulting from the work of an international, multidisciplinary panel addressing chronic spine pain (≥3 months duration) not associated with cancer or https://t.co/PfXM210PsZ
Dr. John Cush @RheumNow ( View Tweet)
Vamorolone, a promising alternative to traditional glucocorticoids for inflammatory diseases.
◦ #Vamorolone is a dissociated steroid compound with reduced side effects.
◦ Unlike conventional #glucocorticoids, vamorolone lacks the hydroxyl or ketone groups and is resistant to https://t.co/yvDWqcbXbn
Alberto Giraldo @alb_giraldo ( View Tweet)
✅ IF YOU ARE LIVING WITH #LUPUS, you can now try #SLAKE, the ONLINE DIGITAL research tool for assessing your ESSENTIAL KNOWLEDGE about #SLE in English, German, Arabic, Spanish, Chinese, Français, Hindi, Indonesian, Dutch, etc... using the following LINK: https://t.co/nSCdBBMEcx https://t.co/PBAPkGynjP
Links:
Laurent ARNAUD @Lupusreference ( View Tweet)
Joint Implant Metals May Be Leaking
Patients with metal-containing joint replacements had significantly higher concentrations of cobalt in their cerebrospinal fluid (CSF) relative to patients without arthroplasties, researchers reported.
Read Article
Cancer Survival with TNF Inhibitors
Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/V10S4oVFsv
https://t.co/MKJKAi0BPV
Dr. John Cush @RheumNow ( View Tweet)
Review article shows that in psoriasis pts, adding #MTX to TNFi increases efficacy, but there is limited data on adding MTX to either IL-17 or IL-23. But in Psoriatic Arthritis (PsA), adding MTX provides no added efficacy compared to biologic monotherapy https://t.co/lNMFZW6XZt https://t.co/RTadfIGZUm
Dr. John Cush @RheumNow ( View Tweet)
NIH Complimentary Medicine overview of Music Therapy - preliminary research suggests that music interventions may be helpful for anxiety, depression, pain control, dementia, multiple sclerosis, Parkinson’s disease, etc https://t.co/RP8X8Kf2jV https://t.co/s0bOTEUCPT
Dr. John Cush @RheumNow ( View Tweet)
EMA approved a record 28 biosimilars in 2024 for cancer, osteoporosis, macular degeneration, and immune-related diseases like plaque psoriasis, ulcerative colitis, and Crohn’s disease https://t.co/MJLvzjwYHX https://t.co/W5aoKwIPVQ
Dr. John Cush @RheumNow ( View Tweet)
From the blog
The effects on rheumatologists and their patients living in Ukraine largely have been unseen by the world. At ACR Convergence 2024, I met Dr. Marta Dzhus who practices at St. Michael's Clinical Hospital in Kyiv; she shared her story with me about the humanitarian crisis in rheumatologic care in Ukraine because of the ongoing war. Here is an excerpt of our conversation.
Read Post
Podcasts
Biomarkers in RA
Cancer Survival with TNF Inhibitors (3.28.2025)-
ERA, APPs, & Alpha GAL (3.21.2025)
-
World Changers (3.14.2025)
Therapeutic Updates
Biomarkers in RA
Sponsored by Augurex
Rheumatologist Dr. Walter Maksymowych discusses the role of biomarkers in RA care, with a focus on 14-3-3eta as a modifiable marker for diagnosis and monitoring disease progression.
Read Post
Poster Hall
